- Title: Subtitle
- Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105)
- Creators
- Mrinal M. Gounder - Memorial Sloan Kettering Cancer CenterMichelle R. Mahoney - Mayo ClinicBrian Andrew Van Tine - Washington University in St. LouisVinod Ravi - The University of Texas MD Anderson Cancer CenterSteven Attia - Mayo Clinic in FloridaHari Anant Deshpande - Yale Cancer CenterAbha A. Gupta - Princess Margaret Cancer CentreMohammed M. Milhem - University of IowaRobert Martin Conry - Kirklin ClinicSujana Movva - Fox Chase Cancer CenterMichael J. Pishvaian - Georgetown University Medical CenterJeffrey Crawford - Duke Medical CenterTarek Sabagh - University of DaytonRobert G. Maki - Cold Spring Harbor LaboratoryWilliam D. Tap - Memorial Sloan Kettering Cancer CenterRobert A Lefkowitz - Memorial Sloan Kettering Cancer CenterNarasimhan P Agaram - Memorial Sloan Kettering Cancer CenterJohn Joseph Wright - National Institutes of HealthAmylou C. Dueck - Mayo Clinic, Scottsdale AZ.Gary K. Schwartz - Columbia University Irving Medical Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.11500-11500
- DOI
- 10.1200/JCO.2018.36.15_suppl.11500
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363186602771
Abstract
Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105)
Journal of clinical oncology, Vol.36(15_suppl), pp.11500-11500
05/20/2018
DOI: 10.1200/JCO.2018.36.15_suppl.11500
Details
Metrics
5 Record Views